"Therapeutic Perspectives of Brivaracetam Against Epilepsy"
نویسندگان
چکیده
Ankur Kumar, Rohit Bhatia and Pooja A Chawla* Author Affiliations Department of Pharmaceutical Chemistry, ISF College Pharmacy, India Received: July 01, 2022 | Published: 06, Corresponding author: Chawla, Chemistry Analysis, Moga-142001, Punjab, DOI: 10.26717/BJSTR.2022.45.007133
منابع مشابه
Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives
Parkinsonism is a progressive motor disease that affects 1.5 million Americans and is the second most common neurodegenerative disease after Alzheimer's. Typical neuropathological features of Parkinson's disease (PD) include degeneration of dopaminergic neurons located in the pars compacta of the substantia nigra that project to the striatum (nigro-striatal pathway) and depositions of cytoplasm...
متن کاملTherapeutic potential of Paclitaxel against COVID-19
The coronavirus disease-2019(COVID-19) was reported in Wuhan, China, in late December 2019 and soon became the most serious global health challenge due to high rate of human-to-human transmission. The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), is a single-stranded RNA virus and belongs to the large Coronaviridae family. Paclitaxel, an antineoplastic drug extracted from the Tax...
متن کاملNew developments in the management of partial-onset epilepsy: role of brivaracetam
Currently, a number of novel anticonvulsant drugs, the so-called third generation, are in various stages of development. Several of them are already available or in ongoing clinical trials. These new compounds should take advantage of new insights into the basic pathophysiology of epileptogenesis, drug metabolism and drug interactions. Many of them still need to be further evaluated mainly in r...
متن کاملProfile of brivaracetam and its potential in the treatment of epilepsy
Brivaracetam (BRV) (UCB 34714) is currently under review by the US Food and Drug Administration and European Medicines Agency for approval as an add-on treatment for adult patients with partial seizures. Similar to levetiracetam (LEV), BRV acts as a high-affinity ligand of the synaptic vesicle protein 2A, however, it has been shown to be 10- to 30-fold more potent than LEV. Moreover, BRV does n...
متن کاملAn open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam
We evaluated nonpsychotic behavioral adverse events (BAEs) in patients receiving levetiracetam (LEV) who switched to brivaracetam (BRV). Patients ≥16 years of age, receiving 2-3 antiepileptic drugs (AEDs), including LEV 1-3g/day, and experiencing BAEs within 16 weeks of LEV treatment initiation, enrolled in an open-label Phase 3b study (NCT01653262) comprising a ≤1-week screening period, an imm...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomedical Journal of Scientific and Technical Research
سال: 2022
ISSN: ['2574-1241']
DOI: https://doi.org/10.26717/bjstr.2022.45.007133